Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21.
View in:
PubMed
subject areas
Acute Kidney Injury
Adenine Nucleotides
Adult
Age Factors
Aged
Alemtuzumab
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Arabinonucleosides
Female
Glomerular Filtration Rate
Hematologic Neoplasms
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute
Lymphoma, Non-Hodgkin
Male
Melphalan
Middle Aged
Recurrence
Risk
Survival Analysis
Transplantation Conditioning
Transplantation, Homologous
authors with profiles
Olatoyosi Odenike
Peter H. O'Donnell
Justin P. Kline
Wendy Stock
Lucy Godley
Richard A. Larson
Koen Van Besien